The high percentage of Her2/neu-positive ovarian carcinomas (29.4%) in the present study is likely due to the inclusion of 39% non-serous carcinomas (mucinous, endometrioid and clear cell types). Here, ERBB2 is linked to serous adenocarcinoma.